Sanofi Acquires Blueprint Medicines in 9.5 Billion Dollar Deal to Boost Rare Disease Therapies

Sanofi has announced the acquisition of Blueprint Medicines Corporation for over $9 billion, marking one of Europe’s largest healthcare deals this year. The acquisition includes a $129 per share cash payment and potential milestone payments, bringing the total valuation to $9.5 billion.

This strategic move strengthens Sanofi’s position in the treatment of rare immunological diseases, particularly systemic mastocytosis. Blueprint’s flagship drug, Ayvakit/Ayvakyt, is the only approved treatment for advanced and indolent systemic mastocytosis in the U.S. and EU. Additionally, the acquisition adds promising pipeline assets, such as elenestinib and BLU-808, which target a wide range of immunological disorders.

Sanofi CEO Paul Hudson emphasized that this acquisition aligns with the company’s vision to become a global leader in immunology. Blueprint’s expertise in immunology and its established network of allergists and dermatologists will boost Sanofi’s market presence.

The deal follows Sanofi’s recent acquisitions of Vigil Neuroscience for $470 million and Inhibrx for $2.2 billion, reflecting its ongoing focus on early-stage and innovative therapies.